Potent antipneumococcal activity of gemifloxacin is associated with dual targeting of gyrase and topoisomerase IV, an in vivo target preference for gyrase, and enhanced stabilization of cleavable complexes in vitro.
about
Characterization of the quinolone resistant determining regions in clinical isolates of pneumococci collected in CanadaDual targeting of topoisomerase IV and gyrase to reduce mutant selection: direct testing of the paradigm by using WCK-1734, a new fluoroquinolone, and ciprofloxacin.Mechanisms and frequency of resistance to gatifloxacin in comparison to AM-1121 and ciprofloxacin in Staphylococcus aureus.Genetic analyses of mutations contributing to fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniaeBactericidal activities of BMS-284756, a novel Des-F(6)-quinolone, against Staphylococcus aureus strains with topoisomerase mutations.Dual targeting of DNA gyrase and topoisomerase IV: target interactions of garenoxacin (BMS-284756, T-3811ME), a new desfluoroquinolone.Nonmolecular test for detection of low-level resistance to fluoroquinolones in Streptococcus pneumoniae.Mechanism of action of and resistance to quinolones.Contribution of the 8-methoxy group to the activity of gatifloxacin against type II topoisomerases of Streptococcus pneumoniae.Topoisomerase targeting with and resistance to gemifloxacin in Staphylococcus aureusNovel antibacterial agents for the treatment of serious Gram-positive infections.Differential effect of P-gp and MRP2 on cellular translocation of gemifloxacinGemifloxacin: a new fluoroquinolone approved for treatment of respiratory infections.Geminofloxacin for the management of community-acquired respiratory tract infections.Multiplex Real-Time Polymerase Chain Reaction-Based Method for the Rapid Detection of gyrA and parC Mutations in Quinolone-Resistant Escherichia coli and Shigella sppMutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates.Gemifloxacin: a new fluoroquinolone.Treatment of community-acquired pneumonia, with special emphasis on gemifloxacin.Fluoroquinolone resistance is a poor surrogate marker for type II topoisomerase mutations in clinical isolates of Streptococcus pneumoniae.Selection and genetic characterization of Streptococcus pneumoniae mutants resistant to the des-F(6) quinolone BMS-284756.Quinolone resistance mutations in Streptococcus pneumoniae GyrA and ParC proteins: mechanistic insights into quinolone action from enzymatic analysis, intracellular levels, and phenotypes of wild-type and mutant proteins.Grepafloxacin, a dimethyl derivative of ciprofloxacin, acts preferentially through gyrase in Streptococcus pneumoniae: role of the C-5 group in target specificity.Cleavable-complex formation by wild-type and quinolone-resistant Streptococcus pneumoniae type II topoisomerases mediated by gemifloxacin and other fluoroquinolones.Topoisomerase mutations associated with in vitro selection of resistance to moxifloxacin in Streptococcus pneumoniaeAccumulation of 10 fluoroquinolones by wild-type or efflux mutant Streptococcus pneumoniae.Antistaphylococcal activities of the new fluoroquinolone JNJ-Q2.Rapid Detection of Genomic Mutations in gyrA and parC Genes of Escherichia coli by Multiplex Allele Specific Polymerase Chain Reaction.Immunomodulatory activities of gemifloxacin in mice.Dual targeting of GyrB and ParE by a novel aminobenzimidazole class of antibacterial compoundsMechanism of action of the antibiotic NXL101, a novel nonfluoroquinolone inhibitor of bacterial type II topoisomerases.Activity of gemifloxacin against quinolone-resistant Streptococcus pneumoniae strains in vitro and in a mouse pneumonia model.Chemiluminescence determination of gemifloxacin based on diperiodatoargentate (III)-sulphuric acid reaction in a micellar medium.
P2860
Q33663032-04BFF264-89CD-4E0C-A777-366579BF926FQ33770013-7BBA0066-9A02-490A-8A46-AFA79014DC4BQ33983092-21EE360D-F7E3-4D07-85EF-4113FDDAA2DEQ33983643-7357FD4A-4B78-4301-8C4F-022DD1F3A67EQ34104362-BFA5DE0F-FF5A-4938-B133-B468AFF6487AQ34142238-BC8D9A71-3CFD-49A2-BABD-D035FFD7DCFFQ34352053-1E105A41-E262-4A82-BE9E-59190A22F084Q34408434-60E04052-B0C0-4FA4-AA5C-087F5FF0CBA9Q34721556-7648CD7E-C213-4E76-B90C-71F8699B5A63Q34725095-E8E162C5-AB58-4CF4-A272-AED162201AC6Q35073345-71BF9A39-0A26-4D50-915E-76C87E384358Q35374935-0E7DB9A8-4C26-4DCE-B38E-05B638719287Q35798789-7F58E020-609C-448B-AB8D-33B823499142Q36724349-38B70753-DE2E-47F7-849D-ECE9061F8477Q37105792-1F5AF6D8-43D1-4B76-A244-97DE8828A6DEQ37568953-8E5A20A6-D135-4536-A64E-FA24584E9DB4Q37867123-E7E4E166-65CA-4FA5-8A7C-2298FC115ACDQ38523119-21E2D25E-862A-48DF-A1C7-E7AA027DC943Q39465570-DBB6D022-A057-4337-9C91-690BAF26BAA9Q39478563-FC52BC44-0F75-4EE6-860C-6A95F6A6C8D5Q39478835-273DAD07-DABB-455D-9A52-C75F2B8B8C00Q39651301-AAB86313-AC65-420C-BA08-4CA885C7E973Q39651324-2C56C02E-8252-4081-A40B-7D2E698545F0Q39652363-6CE8DFE7-09D9-4020-8326-6510B6BAB172Q39653038-B1F83F05-5297-42B0-B61B-F5E0CB21FC14Q39660010-17E91166-9C79-44B6-ACD9-2FFF28804F88Q40481349-72EC8172-70EC-4512-AD08-082A9E7588ACQ41580708-CC4D3550-7E20-4ED9-800B-44D77DC02DBDQ41822811-DB8DC543-9836-4161-B95B-088C16D64DA7Q41925162-86083642-DFEE-4512-BFE5-DAD6DF41D143Q42844652-7A4C4008-D88D-4AC1-9E0B-090FC81075C0Q45997177-472A6297-A350-44DE-8A3D-C1EC506C7466
P2860
Potent antipneumococcal activity of gemifloxacin is associated with dual targeting of gyrase and topoisomerase IV, an in vivo target preference for gyrase, and enhanced stabilization of cleavable complexes in vitro.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
2000年论文
@zh
2000年论文
@zh-cn
name
Potent antipneumococcal activi ...... cleavable complexes in vitro.
@en
Potent antipneumococcal activi ...... cleavable complexes in vitro.
@nl
type
label
Potent antipneumococcal activi ...... cleavable complexes in vitro.
@en
Potent antipneumococcal activi ...... cleavable complexes in vitro.
@nl
prefLabel
Potent antipneumococcal activi ...... cleavable complexes in vitro.
@en
Potent antipneumococcal activi ...... cleavable complexes in vitro.
@nl
P2093
P2860
P1476
Potent antipneumococcal activi ...... cleavable complexes in vitro.
@en
P2093
J E Ambler
L M Fisher
V J Heaton
P2860
P304
P356
10.1128/AAC.44.11.3112-3117.2000
P407
P577
2000-11-01T00:00:00Z